Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Private placement from Amgen grosses $20mm for Provention

Executive Summary

Provention Bio Inc. (treatments for immune mediated diseases) grossed $20mm through a private equity investment made by Amgen, which purchased 2.5mm common shares at $8 apiece. The financing (announced concurrent with a 5mm share public offering completed by Provention) was carried out under the terms of a celiac disease-focused license agreement penned last November between Amgen and Provention.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies